Scarica l'app Stockscreener
12.79
14.73%
-2.21
Dopo l'orario di chiusura:
12.80
0.01
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Precedente Chiudi:
$15.00
Aprire:
$13.525
Volume 24 ore:
8.32M
Relative Volume:
2.70
Capitalizzazione di mercato:
$1.93B
Reddito:
-
Utile/perdita netta:
$-647.68M
Rapporto P/E:
-2.2557
EPS:
-5.67
Flusso di cassa netto:
$-594.49M
1 W Prestazione:
-19.36%
1M Prestazione:
-12.04%
6M Prestazione:
+24.54%
1 anno Prestazione:
-8.71%
Intervallo 1D:
$12.44
$13.84
Intervallo di 1 settimana:
$12.44
$15.80
Portata 52W:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Nome
Biohaven Ltd
Settore
Industria
Telefono
203-404-0410
Indirizzo
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
12.79 | 2.27B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-06 | Iniziato | Goldman | Buy |
| 2026-01-21 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | Downgrade | UBS | Buy → Neutral |
| 2025-11-06 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Iniziato | Citigroup | Buy |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-05-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-09-16 | Iniziato | Jefferies | Buy |
| 2024-09-04 | Iniziato | Bernstein | Outperform |
| 2024-07-24 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2023-12-22 | Iniziato | H.C. Wainwright | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-01-24 | Iniziato | SVB Securities | Outperform |
| 2023-01-04 | Iniziato | JP Morgan | Overweight |
| 2022-12-02 | Iniziato | BTIG Research | Buy |
| 2022-10-26 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Iniziato | Piper Sandler | Overweight |
| 2022-08-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-05-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Downgrade | UBS | Buy → Neutral |
| 2021-08-03 | Reiterato | Canaccord Genuity | Buy |
| 2021-03-11 | Iniziato | UBS | Buy |
| 2020-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-17 | Iniziato | Cowen | Outperform |
| 2020-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2019-11-22 | Iniziato | Wedbush | Outperform |
| 2019-06-25 | Reiterato | Canaccord Genuity | Buy |
| 2019-05-06 | Iniziato | Goldman | Buy |
| 2019-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Reiterato | Needham | Buy |
| 2018-07-03 | Reiterato | Needham | Buy |
| 2018-07-02 | Reiterato | Needham | Buy |
| 2018-04-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Reiterato | Canaccord Genuity | Buy |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-03 | Reiterato | Needham | Buy |
Mostra tutto
Biohaven Ltd Borsa (BHVN) Ultime notizie
Biohaven’s Newly Out-Licensed Epilepsy Drug Put On A Partial Clinical Hold - insights.citeline.com
Biohaven: The Hold Isn't The Problem (Rating Downgrade) (NYSE:BHVN) - Seeking Alpha
BHVN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
FDA pauses enrollment in Biohaven’s opakalim trials; pivotal readout remains on track - AllSci
Why is Biohaven Pharmaceutical stock sliding today? - Investing.com
BHVN Stock Slips As Kv7 Deal Seen As Stopgap Move - StocksToTrade
BHVN Stock Slips As SK Deal Seen As Buying Time - timothysykes.com
Baird reiterates Biohaven stock rating after regulatory update - Investing.com
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com Canada
US FDA pauses new enrollment in Biohaven's epilepsy drug trials - Reuters
Why Is Biohaven Stock Tumbling Today?Biohaven (NYSE:BHVN) - Benzinga
FDA Places Partial Clinical Hold on Biohaven’s BHV-7000 Epilepsy Enrollment - Minichart
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials - finance.yahoo.com
BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold? - finance.yahoo.com
FDA places partial hold on Biohaven’s epilepsy drug - finance.yahoo.com
Biohaven stock tumbles after pausing trial enrollment By Investing.com - Investing.com Australia
Biohaven stock tumbles after pausing trial enrollment - Investing.com
Biohaven faces partial FDA hold on BHV-7000 program - TipRanks
Form 8K Biohaven Pharmaceutical Holding Co For: 10 September By Investing.com - Investing.com Canada
Biohaven pauses new enrollment in epilepsy trials after FDA partial clinical hold - Investing.com Canada
Is Biohaven (BHVN) Priced At A Premium After Its 36% Rise? - simplywall.st
Technical Reactions to BHVN Trends in Macro Strategies - Stock Traders Daily
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout - Stocktwits
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts - Stocktwits
Biohaven Pharma stock falls after RBC Capital downgrade By Investing.com - Investing.com India
Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says - marketscreener.com
Biohaven stock downgraded at RBC Capital Markets (BHVN:NYSE) - Seeking Alpha
Biohaven Pharma stock falls after RBC Capital downgrade - Investing.com
BHVN Downgraded by RBC Capital -- Price Target Lowered to $19.00 - GuruFocus
RBC Downgrades Biohaven to Sector Perform From Outperform, Cuts Price Target to $19 From $23, Keeps Speculative Risk - marketscreener.com
Biohaven Shares Fall After RBC Downgrades Stock and Cuts Price Target - finance.yahoo.com
Why is Biohaven Pharmaceutical stock sliding today? By Investing.com - Investing.com Canada
RBC Capital downgrades Biohaven Pharma stock rating on valuation By Investing.com - Investing.com South Africa
Did Biohaven’s Kv7 Deal With SK Biopharmaceuticals Just Reshape BHVN’s Risk And Funding Profile? - simplywall.st
Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet - finance.yahoo.com
With an ion the bottom line, Biohaven signs SK epilepsy deal - BioWorld News
Biohaven (BHVN) Is Up 11.3% After Out-Licensing Kv7 Platform To SK Biopharm For Up To $795M - webull.com
Is Biohaven (BHVN) A Bargain On Its SK Biopharma Licensing Deal? - simplywall.st
Precision Trading with Biohaven Ltd. (BHVN) Risk Zones - Stock Traders Daily
Why Biohaven Stock Was Rocking the Market This Week - finance.yahoo.com
Biohaven advances key drug trials and secures $350M deal with SK Biopharmaceuticals - Pluang
Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels - Seeking Alpha
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program - finance.yahoo.com
Why Biohaven Ltd. (BHVN) Stock Is Up Today - Quiver Quantitative
Biohaven Ltd. And SK Biopharmaceuticals Co., Ltd. Enter Into Global Licensing Agreement For Kv7 Ion Channel Platform And Opakalim - marketscreener.com
Biohaven stock surges 7% on SK Biopharmaceuticals deal By Investing.com - Investing.com Australia
Biohaven licenses Kv7 epilepsy platform to SK Biopharma for up to $795M - StreetInsider
SK Bio taps up Biohaven for Kv7 platform and epilepsy drug in USD 795m deal - AllSci
Biohaven stock surges 7% on SK Biopharmaceuticals deal - Investing.com
Biohaven (NYSE: BHVN) offloads epilepsy drug costs in rich global licensing pact - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday SessionBiohaven (NYSE:BHVN), SCYNEXIS (NASDAQ:SCY - Benzinga
Biohaven Ltd Azioni (BHVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):